Market capitalization | $62.98m |
Enterprise Value | $17.11m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.29 |
P/S ratio (TTM) P/S ratio | 4.75 |
P/B ratio (TTM) P/B ratio | 1.08 |
Revenue growth (TTM) Revenue growth | 35.67% |
Revenue (TTM) Revenue | $13.26m |
As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.
3 Analysts have issued a Hyperfine forecast:
3 Analysts have issued a Hyperfine forecast:
Sep '24 |
+/-
%
|
||
Revenue | 13 13 |
36%
36%
|
|
Gross Profit | 6.10 6.10 |
52%
52%
|
|
EBITDA | -43 -43 |
12%
12%
|
EBIT (Operating Income) EBIT | -44 -44 |
12%
12%
|
Net Profit | -41 -41 |
12%
12%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Hyperfine, Inc. is a medical device development company, which is engaged in the development of, MRI solutions and non-invasive neural monitoring technology. The company was founded by Jonathan M. Rothberg on February 25, 2014 and is headquartered in Guilford, CT.
Head office | United States |
CEO | Maria Sainz |
Employees | 131 |
Founded | 2014 |
Website | www.hyperfine.io |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.